Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass

Annals of Thoracic Surgery

Volumn 77, Issue 2, 2004, Pages 644-650

  Kaminishi, Yuichiro ^b   Hiramatsu, Yuji ^a   Watanabe, Yasunori ^b   Yoshimura, Yukihiro ^b   Sakakibara, Yuzuru ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; APROTININ; BETA THROMBOGLOBULIN; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; GUANIDINE DERIVATIVE; HEPARIN; INTERLEUKIN 6; LEUKOCYTE ELASTASE; NAFAMSTAT; NAFAMSTAT MESILATE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HUMAN; INHIBITION KINETICS; JAPAN; MALE; METABOLISM; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS;

EID: 0442292364     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)01513-3     Document Type: Article

References (27)

1. Edmunds L.H. Jr. Why cardiopulmonary bypass makes patients sick: strategies to control the blood synthetic surface interface. Karp R.B., Laks H., Wechsler A.S. Advances in Cardiac Surgery. 1995;131-167 Mosby-Year Book Inc, Chicago.
2. Royston D. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol. 27:(Suppl I):1996;S42-49.
3. Brister S.J., Ofosu F.A., Buchanan M.R. Thrombin generation during cardiac surgery is heparin the ideal anticoagulant? Thromb Haemost. 70:(2):1993;259-262.
4. Gorman J.H. III, Edmunds L.H. Jr. Blood anesthesia for cardiopulmonary bypass. J Card Surg. 10:1995;270-279.
5. Edmunds L.H. Jr. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 66:1998;S12-16.
6. Waxman L., Smith D.E., Arcuri K.E., Vlasuk G.P. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science. 248:1990;593-596.
7. Gikakis N., Khan M.M.H., Hiramatsu Y., et al. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation. Circulation. 94:(Suppl II):1996;II-341-346.
8. Fujii S., Hitomi Y. New synthetic inhibitors of C1r, C1, elastase, thrombin, plasmin, kallikrein and trypsin. Biochem Biophys Acta. 661:1981;342-345.
9. Sundaram S., Gikakis N., Hack C.E., et al. Nafamostat mesilate, a broad-spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost. 75:1996;76-82.
10. Usui A., Hiroura M., Kawamura M., et al. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials. Ann Thorac Surg. 62:1996;1404-1411.
11. Murase M., Usui A., Tomita Y., Maeda M., Koyama T., Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation. 88:1993;432-436.
12. Sawa Y., Shimazaki Y., Kadoba K., et al. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg. 111:1996;29-35.
13. Tanaka K., Kondo C., Takagi K., et al. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery. ASAIO J. 39:1993;M545-549.
14. Fritz H., Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 33:1983;479-494.
15. Oeveren W., Harder M.P., Roozendaal K.J., Eijsman L., Wildevuur C.R.H. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;788-797.
16. Primack C., Walenga J.M., Koza M.J., Shankey T.V., Pifarre R. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann Thorac Surg. 61:1996;1188-1193.
17. Ray M.J., Marsh N.A. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost. 78:1997;1021-1026.
18. Hayashida N., Isomura T., Sato T., Maruyama H., Kosuga K., Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg. 114:1997;261-269.
19. Dignan R.J., Law D.W., Seah P.W., et al. Ultra-low dose aprotinin decreases transfusion requirements, and is cost effective in coronary operations. Ann Thorac Surg. 71:2001;158-164.
20. Holland B.S., Copenhaver M.D. An improved sequential rejective Bonferroni test procedure. Biometrics. 42:1987;417-423.
21. Wachtfogel Y.T., Harpel P.C., Edmunds L.H. Jr, Colman R.W. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha2-plasmin inhibitor complexes during cardiopulmonary bypass. Blood. 73:1989;468-471.
22. Wachtfogel Y.T., Kucich U., James H.L., et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest. 72:1983;1672-1677.
23. Issekutz A.C., Roland D.M., Patrick R.A. The effect of FUT-175 on C3a, C4a and C5a generation in vitro and inflammation reactions in vivo. Int J Immunopharmacol. 12:1990;1-9.
24. Chung J.H., Gikakis N., Rao A.K., Drake T.A., Colman R.W., Edmunds L.H. Jr. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation. 93:1996;2014-2018.
25. Kappelmayer J., Bernabei A., Edmunds L.H. Jr, Edgington T.S., Colman R.W. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res. 72:1993;1075-1081.
26. Sato T., Tanaka K., Kondo C., et al. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery. ASAIO Transactions. 37:1991;M194-195.
27. Hitomi Y., Ikari N., Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Hemostasis. 15:1985;164-168.